WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H556330
CAS#: 1793080-72-4
Description: VX-150, also known as EOS-62073, is a pro-drug of a highly selective NaV1.8 inhibitor. VX-150 is an orally bioavailable pro-drug that rapidly converts into its active moiety, which is a highly selective inhibitor of NaV1.8 relative to the other sodium channel subtypes (>400-fold).
Hodoodo Cat#: H556330
Name: VX-150
CAS#: 1793080-72-4
Chemical Formula: C21H17F4N2O7P
Exact Mass: 516.07
Molecular Weight: 516.341
Elemental Analysis: C, 48.85; H, 3.32; F, 14.72; N, 5.43; O, 21.69; P, 6.00
Synonym: VX-150; VX 150; VX150; EOS-62073; EOS 62073; EOS62073;
IUPAC/Chemical Name: N-[1,2-Dihydro-2-oxo-1-[(phosphonooxy)methyl]-4-pyridinyl]-2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamide
InChi Key: SQDQNNKQTHOQHO-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H17F4N2O7P/c1-12-8-14(22)3-5-17(12)34-18-9-13(21(23,24)25)2-4-16(18)20(29)26-15-6-7-27(19(28)10-15)11-33-35(30,31)32/h2-10H,11H2,1H3,(H,26,29)(H2,30,31,32)
SMILES Code: O=C(NC(C=CN1COP(O)(O)=O)=CC1=O)C2=CC=C(C(F)(F)F)C=C2OC3=CC=C(F)C=C3C
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 516.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Hijma HJ, Siebenga PS, de Kam ML, Groeneveld GJ. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults. Pain Med. 2021 Aug 6;22(8):1814-1826. doi: 10.1093/pm/pnab032. PMID: 33543763; PMCID: PMC8346919.
2. Alles SRA, Smith PA. Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets. Front Pain Res (Lausanne). 2021 Dec 13;2:750583. doi: 10.3389/fpain.2021.750583. PMID: 35295464; PMCID: PMC8915663.